By Alberto Amalfi | Thursday, December 9, 2022
Kamil Majchrzak's competitive career is in limbo after he failed recent doping tests.
World No. 77 Majchrzak has been provisionally suspended under Article 7.12.1 of the 2022 Tennis Anti-Doping Program (TADP), the International Tennis Integrity Agency announced today. The suspension means he's unable to compete or even attend pro tennis tournaments sanctioned by the game's governing bodies.
More: Federer's Plans for Fans
The ITIA sent the Polish player pre-charge notice of an Anti-Doping Rule Violation on November 30th under Article 2.1 of the Program (presence of a Prohibited Substance in a Player’s Sample) and/or Article 2.2 (Use of a Prohibited Substance without a valid TUE).
Majchrzak said on social media he's innocent of knowingly doping.
"Firstly, I have never, ever knowingly taken any banned substance," Majchrzak said in an Instagram post. "At this moment, I have no idea what happened and this is the biggest shock.
"I have started the most difficult fight of my life—the fight to prove my innocence and return to the sport I love."
The 26-year-old Pole provided samples while competing at three events – the Sofia Open in September, Japan Open in October and the FILA Open Seoul Challenger in October.
The samples from each of these tests were split into A and B samples and the subsequent analysis of the A samples found that:
One sample contained SARM S-22 and a metabolite of LGD-4033
Two samples contained SARM S-22 and metabolites of a PPARδ agonist
SARM S-22, LGD-4033 and PPARδ agonists are all non-Specified substances listed in the 2022 World Anti-Doping Agency (WADA) Prohibited List. Adverse Analytical Findings for non-Specified Substances carry a mandatory provisional suspension.
Majchrzak has the right to request that the B samples are analyzed to see if they confirm the A sample findings. Majchrzak is the second player in recent weeks to be hit with a doping suspension.
Spanish veteran Fernando Verdasco was hit with a two-month doping suspension last month after testing positive for an ADHD medication.
Photo credit: Getty